Overexpression of the lipogenic enzyme fatty acid synthase (FAS) is a common molecular feature in subsets of sex-steroid-related tumors including endometrium and breast carcinomas that are associated with poor prognosis. Pharmacological inhibition of tumor-associated FAS hyperactivity is under investigation as a chemotherapeutic target. We examined the effects of the mycotoxin cerulenin (a covalent FAS inactivator), and the novel small compound C75 (a slow-binding FAS inhibitor) on estradiol (E 2 )-and tamoxifen (TAM)-stimulated ERdriven molecular responses in Ishikawa cells, an in vitro model of well-differentiated human endometrial carcinoma. We evaluated the effects of FAS inhibition on E 2 -and TAM-induced estrogen receptor (ER) transcriptional activity by using transient cotransfection assays with an estrogen-response element reporter construct (ERE-Luciferase). Antiestrogenic effects of cerulenin and C75 were observed by dose-dependent inhibition of E 2 -stimulated ERE-dependent transcription, whereas FAS inhibitors did not significantly increase the levels of ERE transcriptional activity in the absence of E 2 . Moreover, pharmacological blockade of FAS activity completely abolished TAMstimulated ERE activity. To address the reliability of transient transfection assays, the effects of FAS inhibitors on E 2 -inducible gene products were evaluated. FAS blockade induced a dose-dependent decrease in E 2 -inducible alkaline phosphatase activity. E 2 -stimulated accumulation of progesterone receptor (PR) and HER-2/neu oncogene was abolished in the presence of FAS blockers. FAS inhibition also resulted in a marked downregulation of E 2 -stimulated ERa expression, and noticeably impaired E 2 -induced ERa nuclear accumulation. A dose-dependent decrease in cell proliferation and cell viability was observed after FAS blockade. A Cell Death ELISA, detecting DNA fragmentation, demonstrated that FAS inhibitors stimulated apoptosis of Ishikawa cells. The analysis of critical E 2 -and TAMrelated cell cycle proteins revealed an increase of both the expression and the nuclear accumulation of cyclindependent kinase inhibitors p21 WAF1/CIP1 and p27 Kip1 following FAS inhibition. To rule out non-FAS ceruleninand C75-related effects, we finally monitored ER signaling after silencing of FAS gene expression using the highly sequence-specific mechanism of RNA interference (RNAi). 
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The biosynthetic enzyme fatty acid synthase (FAS) is the major enzyme required for the anabolic conversion of dietary carbohydrate to fatty acids, and it functions normally in the liver to make lipids for export to metabolically active tissues or storage in adipose tissue (Roncari, 1974; Wakil, 1989; Witkowski et al., 1991) . On the contrary, FAS is minimally expressed in most other normal human tissues because they appear to utilize preferentially circulating lipids for the synthesis of new structural lipids (Weiss et al., 1986) . Remarkably, under normal conditions, FAS is highly expressed in hormone-sensitive cells (Kusakabe et al., 2000) . During the menstrual cycle, the expression of FAS in the human endometrium is closely linked to the expression of the proliferation antigen Ki-67, ERa, and progesterone receptor (PR), suggesting a connection between FAS and the ERa-dependent signaling in endometrial cell proliferation. Thus, FAS expression increases in endometrial glands and stromal cells from the proliferative to the early secretory phase, and after cessation of cell proliferation in the mid-to the late-secretory phase, the endometrial tissues become FAS negative (Escot et al., 1990; Pizer et al., 1997) . Strikingly, overexpression and hyperactivity of FAS is a common molecular feature in subsets of sex-steroid-related tumors including endometrium breast, ovarian, and prostate carcinomas (Jensen et al., 1993; Alo et al., 1996 Alo et al., , 1999 Shurbaji et al., 1996; Gansler et al., 1997; Pizer et al., 1998b; Swinnen et al., 2002) . Interestingly, upregulation of FAS expression is an early event in tumor development; it is more pronounced in more advanced tumors and it often correlates with a poor prognosis (Milgraum et al., 1997; Kuhajda, 2000a; Swinnen et al., 2002) . Although the mechanism of FAS overexpression in tumors is not completely understood, it has been shown that estradiol (E 2 ), progesterone, and androgens have a role in FAS regulation in hormonally responsive tumors. Thus, FAS expression is part of the E 2 -driven cellular response that leads to proliferation in hormone-dependent endometrial carcinoma cells and associated with higher endometrial tumor grades (Pizer et al., 1998b) . E 2 , progesterone, and synthetic progestins also stimulate cell growth and concomitant FAS expression in hormone-dependent human breast cancer cells such as MCF-7 and T47-D (Joyeux et al., 1989; Chalbos et al., 1992; Kalkhoven et al., 1994) . In the androgendependent prostate cancer cell line LNCaP, androgens have been shown to stimulate coordinate expression of FAS and enzymes involved in cholesterol synthesis (Swinnen et al., 1997; Heemers et al., 2001) . Moreover, the recent identification of a novel FAS/ERa fusion transcript expressed in a variety of human cancer cell lines including prostate, breast, cervical, and bladder cancer cells further suggests a close linkage between FAS and the ERa signaling pathway (Ye et al., 2000) .
Nevertheless, several studies using chemical inhibitors of FAS activity have shown that specific blockage of its activity significantly attenuates the growth and survival of tumor cells, suggesting that tumor-associated FAS hyperactivity is vital for the survival of human cancer cells and further identifying FAS as a target pathway for chemotherapy development. The mycotoxin cerulenin ([2S,3R] 2,3-epoxy-4-oxo-7E,10E-dodecadienamide), a potent noncompetitive inhibitor of FAS activity (Vance et al., 1972; Omura, 1976; Christie et al., 1981) , is cytotoxic for different human cancer cells in vitro, and slows the development of ovarian cancer xenografts in mice in vivo (Pizer et al., 1996a (Pizer et al., , b, 1998a . Cerulenin, a natural product derived from the fungus Cephalosporium caerulens, is a suicide inhibitor that binds irreversibly to the catalytic binding site of the b-ketoacyl-acyl carrier protein synthase in the multienzyme FAS complex (Moche et al., 1999; Price et al., 2001) . While cerulenin has been reported to exhibit other effects, these occur mainly in nonmammalian systems and at cerulenin concentrations significantly higher than those used in the current study (Omura, 1976; Moelling et al., 1990; Perez and Carrasco, 1991; Simon and Aderem, 1992) . By taking advantage of the well know ability of cerulenin to specifically block FAS-dependent de novo fatty acid biosynthesis (Vance et al., 1972; Omura, 1976; Christie et al., 1981) , we assessed the role of tumorassociated FAS hyperactivity on E 2 -and TAM-stimulated ER-driven molecular responses and evaluated to which extent pharmacological inhibition of FAS activity results in growth inhibition and/or apoptotic cell death in human endometrial adenocarcinoma cells. To further establish the ability to pharmacologically inhibit FAS activity, and to provide additional evidence that FAS-dependent endogenous lipogenesis is the major mechanism modulating ER signaling in endometrial adenocarcinoma cells, a second FAS inhibitor C75 was used. The a-methylene-g-butyrolactone C75 is a synthetic, chemically stable inhibitor of FAS activity that has recently become available (Kuhajda et al., 2000b) . Structurally, C75 lacks the reactive epoxide present on cerulenin, enhancing chemical stability and specificity. C75 inhibits purified mammalian FAS with characteristics of a slow-binding inhibitor, induces cytostatic and cytotoxic effects in cultured tumor cells, and exhibits significant growth inhibitory effects on human breast cancer xenografts (Kuhajda et al., 2000b; Pizer et al., 2000; Li et al., 2001) . Primary human endometrial cell cultures provide an excellent model to study the physiological effects of ovarian steroids on ER-driven signaling, but are difficult to obtain in sufficient amounts for biochemical studies. Ishikawa cells, derived from a well-differentiated human endometrial adenocarcinoma, are reported to express endogenous ER and have been used in numerous research areas such as reproductive biology and molecular science, thus providing a relevant model system for the study of E 2 -regulated endometrial gene expression (Albert et al., 1990; Lessey et al., 1996; Pisha and Pezzuto, 1997; Krishna and Pezzuto, 2001; Nishida, 2002; Sakamoto et al., 2002) . This cell line therefore is an ideal candidate to investigate the effects of FAS inhibitors cerulenin and C75 on E 2 -and TAMmodulated endometrial tumor cell behavior.
To demonstrate cerulenin specificity, FAS activity was determined in the particle-free supernatants of Ishikawa cells treated with 2.5, 5 and 10 mg/ml cerulenin by measuring the linear increase in NADPH oxidation following the addition of malonyl-CoA (Dils and Carey, 1975) . Cerulenin induced up to 90% inhibition of FAS activity compared with untreated cells after 6 h exposure. However, despite the significant drop in FAS activity, Ishikawa cells retained 495% viability. C75 treatment of Ishikawa cells showed similar magnitudes of FAS activity inhibition (up to 80%). To evaluate the effects of pharmacological inhibition of tumor-associated FAS hyperactivity on ER-transactivation and ligand responsiveness in human endometrial adenocarcinoma cells, we performed transient assays. Ishikawa cells were cotransfected with a luciferase reporter gene linked to an estrogen response element (ERE-Luciferase) and the internal control vector (pRL-CMV), and evaluated for changes in the levels of basal (untreated) and E 2 -induced reporter activity ( Figure 1a ). E 2 (10 À9 M), as a single agent, caused a sevenfold increase in luciferase activity relative to basal levels in untreated control cells. ICI 182,780, a pure ER antagonist, was used as a control to demonstrate that ER did mediate this E 2 -dependent increase in luciferase activity. Cotreatment with ICI 182,780 (10 À7 M) antagonized E 2 -induced luciferase activity by 99%, whereas treatment with ICI 182,780 alone had no significant effect on ER-mediated luciferase transcriptional activation (data not shown). In the absence of E 2 , the basal ER-dependent transcriptional levels were slightly increased in Ishikawa cells treated with low concentrations of cerulenin and C75 (o5 mg/ml) in comparison to untreated control cells, while ERdependent luciferase transcriptional activation was unaffected in the presence of higher concentrations (45 mg/ ml) of cerulenin and C75. To examine the mechanism underlying the ability of FAS blockers to transactivate ER signaling, we took advantage of our recent results demonstrating that the inhibition of FAS activity activates the Raf-mitogen-activated protein kinase kinase (MEK)-extracellular-signal-regulated kinase (ERK1/ ERK2) pathway in human breast cancer cells (Menendez et al., 2003) . The ER cross talks with a number of mitogenic signaling pathways and second messengers, including MAPK, and this molecular interaction may support ligand-independent ER transcription. In fact, it has been shown that MAPK hyperactivity promotes the increased association of the ER with coactivators and decreased association with corepressors, thus favoring E 2 -independent gene transcription (Kato et al., 1995; Bunone et al., 1996; Atanaskova et al., 2002) . We therefore hypothesized that FAS inhibitors may also perhaps target the Raf-MEK-ERK prosurvival pathway in endometrial cancer cells, thus inducing ER transcriptional activity in an E 2 -independent manner. When the activation of the Raf-MEK-MAPK pathway was monitored by Western blotting analyses with polyclonal antibodies recognizing the activated form of the ERK1/ ERK2 enzymes, we observed a significant activation of Raf/MAPK ERK1/ERK2 signaling pathway in Ishikawa cells treated with low concentrations of FAS inhibitors. The pure ER antagonist ICI 182,780 and U0126, a noncompetitive inhibitor of the dual specificity MAPK kinases MEK 1 and MEK2 (Favata et al., 1998) , the enzymes that activate MAPK, completely unmasked the weak agonistic effect of FAS inhibitors on ERE-mediated luciferase reporter activity (data not shown), suggesting that cerulenin-and C75-induced activation of MAPK may increase ERE reporter activity in the absence of E 2 by enhancing an MAPK-ER cross-talk. In contrast, FAS inhibitors cerulenin and C75 exhibited dose-dependent antiestrogenic activity when combined with E 2 . The effect was maximal at 10 mg/ml cerulenin and C75, where B70 and 100% inhibition of E 2 -induced luciferase activity was observed, respectively. These results demonstrate that pharmacological inhibition of FAS activity enhances to some extent ER transcriptional activity in a ligand (E 2 )-independent manner. More importantly, cerulenin-and C75-induced inhibition of FAS activity acts as a potent antiestrogen since it blocks E 2 -dependent activation of ER and ER-mediated transcriptional activity in ERpositive endometrial adenocarcinoma cells.
We also investigated the effects of FAS inhibitors cerulenin and C75 on the agonist activity of TAM in endometrial adenocarcinoma Ishikawa cells using ERE reporter plasmids. TAM stimulated ERE transactivation in a dose-dependent manner (up to fivefold at 10 À8 M TAM) and it did not suppress E 2 -stimuladed ERa-dependent transcriptional activity (Figure 1b) . Moreover, the pure antiestrogen ICI 182,780 had no effect on the TAM-induced ERE transcriptional activity in Ishikawa cells. Therefore, we next assessed the effects of cerulenin and C75 on the agonist activity of TAM on ER-mediated transcriptional activity. Remarkably, TAM induction of ERE transcriptional activity was abolished in a dose-related manner by cotreatment with FAS blockers, and 100% inhibition was observed at 10 mg/ml cerulenin and C75. The ability of TAM to activate ERa-dependent transcriptional activity in the absence or presence of E 2 and the inability of ICI 182,780 to inhibit TAM-stimulated ER transcriptional activity in Ishikawa cells is consistent with an E 2 -independent agonist action of TAM on ER signaling in endometrial carcinoma cells (Sakamoto et al., 2002) . Interestingly, our results indicate that pharmacological inhibition of FAS activity completely antagonizes the agonistic activity of TAM on ER transcriptional activity in ER-positive endometrial adenocarcinoma cells.
It may be suggested that transient transfection experiments do not fully recapitulate in vivo conditions required to observe antiestrogenic activities. Thus, to address the reliability of transient transfection assays, we also evaluated the effect of FAS inhibition on several E 2 -inducible markers. The expression and activity of the enzyme alkaline phosphatase (AP) is under strict estrogenic control at the transcriptional level in Ishikawa cells (Albert et al., 1990) , and this property has been exploited to develop a suitable assay for identifying antiestrogenic plant extracts (Pisha and Pezzuto, 1997; Lupu et al., 2003) . E 2 causes an increase in AP activity in Ishikawa cells and this response can be inhibited by pure antiestrogens (Simard et al., 1997) . Therefore, we used this multiwell in vitro bioassay based on the E 2 -specific and dose-dependent enhancement of AP activity in the human endometrial adenocarcinoma cell line Ishikawa to additionally characterize the antiestrogenic effects resulting from FAS inhibition. Cells were grown in phenol red-free IMEM that contained steroidstripped FBS for all of the studies, and E 2 , which induces AP activity at levels as low as 10 À9 M, was used as positive control. When Ishikawa cells were treated with this concentration of E 2 , a 10-fold increase in AP activity was observed as compared to the negative control (ethanol). The pure ER antagonist ICI 182,780 fully inhibited these effects, demonstrating the ER dependency of this process ( Figure 1c ). To evaluate an estrogenic effect of C75, this compound was tested at different concentrations in the absence of E 2 . Treatment of Ishikawa cells with C75 (concentrations as high as 5 mg/ml) did not significantly increase the levels of E 2 -inducible marker AP (Figure 1d ). On the other hand, when AP activity was induced by treatment with 10 À9 M of E 2 , C75 exhibited a marked dose-dependent antiestrogenic effect, as evident from a 70% decrease in the induction of AP activity ( Figure 1c ). The IC 50 was calculated as 2.0 mg/ml C75. C75-related cytotoxicity did not contribute to its antiestrogenic effect at any of the concentrations used, as judged by parallel studies in which growth inhibition was assessed using 0.4% sulforhodamine B dye. An analogous antiestrogenic effect was also observed when the FAS inhibitor cerulenin was used (B65% decrease in the induction of AP activity at 5 mg/ml cerulenin).
We next examined whether the inhibition of FAS activity also regulated well-documented E 2 -responsive genes. We first tested progesterone receptor (PR), which has been shown to be upregulated by E 2 in Ishikawa cells (Lessey et al., 1996) . After changing to estrogenfree medium for 3 days, the basal level of PR expression in Ishikawa cells was minimal. Using an incubation period of 48 h, cerulenin and C75 were tested at four different concentrations with or without E 2 . As shown in Figure 1d , PR expression was not induced by FAS inhibitors at any of the concentrations evaluated. When administered with E 2 , a remarkable downregulation of E 2 -induced accumulation of PR was observed at concentrations of cerulenin and C75 X6 mg/ml. In fact, 10 mg/ml cerulenin and C75 downregulated E 2 -stimulated upregulation of PR to a level comparable with that found in the E 2 -free control samples. Immunostaining of Ishikawa cells demonstrated that PR was localized predominantly in the Ishikawa cell nuclei (Figure 1d , panel i). E 2 treatment significantly enhanced the PR intensity compared with the control (Figure 1d , panel ii), and C75 treatment suppressed this effect when combined with E 2 (Figure 1d , panel iii).
Expression of the HER-2/neu oncogene is under transcriptional control of E 2 -activated ERa, and it has been reported that E 2 significantly increases the content of HER-2/neu protein in Ishikawa cells (Markogiannakis et al., 1997; Hata et al., 1998) . Moreover, the kinetic of the estrogenic induction of HER-2/neu and Ishikawa cell proliferation suggests a causal link between HER-2/neu expression and Ishikawa cell proliferation (Markogiannakis et al., 1997) . Therefore, we assessed the effect of FAS activity blockade on HER-2/ neu expression after E 2 stimulation in Ishikawa cells. As predicted, Ishikawa cells showed a significant induction of HER-2/neu expression after treatment with 10 À9 M E 2 . Remarkably, E 2 -induced HER-2/neu was downregulated in a dose-dependent manner in the presence of increasing concentrations of C75 (Figure 1d ). In fact, 10 mg/ml C75 downregulated E 2 -stimulated upregulation of HER-2/neu to a level lower than that found in the Figure 1 (a, b) Pharmacological inhibition of FAS activity antagonizes E 2 -and TAM-induced activation of ERE-driven reporter activity in transient transfected Ishikawa cells. Ishikawa endometrial carcinoma cells were propagated in E 2 -deprived (phenol red-free) IMEM with 5% CCS for 5 days before the onset of experiments to ensure complete depletion of estradiol-like compounds from the media. For transfection experiments, the cells were seeded into 12-well plates at a density of 10 Â 10 4 cells/well. Using FUGene 6 reagent (Roche Biochemicals, Indianapolis, IN, USA) according to the manufacturer's instructions, the cells were transfected with 0.75 mg/well of the estrogen-responsive reporter, ERE-Luciferase, containing a Vitellogenin A 2 -derived ERE along with 0.05 mg/well of the internal control plasmid pRL-CMV, used to correct for transfection efficiency. After 18 h, the transfected cells were washed and then incubated in fresh medium containing 5% CCS supplemented with E 2 (10 À9 M), ICI 182,780 (10 À7 M), TAM (10
À9
-10 À8 M), cerulenin (1-10 mg/ml), C75 (1-10 mg/ml), combinations of these compounds as specified, and ethanol (v/v) or DMSO (v/v) vehicles alone. Approximately 24 h after treatments, luciferase activity from cell extracts was detected using a Luciferase Assay System (Promega, Madison, WI, USA) according to the protocol specified by the manufacturer using a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA, USA). The magnitude of activation in ERE-Luciferase-transfected cells treated with vehicle was determined after normalization to the activity of pRL-CMV and then taken as 1.0-fold. This control value was used to calculate the relative (fold) change in transcriptional activities of ERE-Luciferasetransfected cells in response to treatments after normalization to pRL-CMV activity. All data have been normalized as the ratio of raw light units to pRL-CMV units corrected for pRL-CMV activity, and are shown as the mean (columns)7s.d. (bars) from three separate experiments (performed in triplicate). (c) Pharmacological inhibition of FAS activity suppresses E 2 -inducible alkaline phosphatase (AP) activity in Ishikawa cells. The standard assay has been described in detail elsewhere (Pisha and Pezzuto, 1997; Lupu et al., 2003) . Briefly, 5 days before patting the cells, the medium was changed to a phenol red-free formulation of IMEM containing charcoal-dextran-stripped FBS to remove estrogens (estrogen-free medium). Cell suspensions (190 ml containing 5 Â 10 4 cells) were plated onto 96-well microtiter plates and incubated overnight at 371C in a 5% CO 2 incubator. C75 (10 ml dissolved in DMSO, diluted 10-fold in ethanol, and then diluted 10-fold in complete phenol red-free medium to reduce any inductive effects of DMSO and ethanol), either alone or with 2 Â 10 À6 M E 2 , and the relevant controls (DMSO, E 2 , and ICI 182,780) were added to the plated cells and incubated for 4 days. The plates were processed by removing the test medium, washing twice with PBS, adding 50 ml of 0.1% Triton X-100 (v/v) in 0.1 M Tris-HCl buffer (pH 9.8), and freezing at À801C. For analysis, the plates were rapidly thawed at 371C, and 150 ml of 0.1 M Tris-HCl buffer (pH 9.8) containing 1 mg/ml of p-nitrophenyl phosphate were added to each cell. The plates were monitored at 405 nm with an ELISA reader every 15 s with a 10 s shake between each reading for the first 8 min. The slopes of the obtained curves were calculated, and those obtained with cell preparations treated with test samples were compared with standards. À9 M E 2 (48 h) were washed twice with PBS and then lysed in buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate, 1 mM Na 3 VO 4 , 1 mg/ml leupeptin, 1 mM phenylmethylsulfonylfluoride) for 30 min on ice. The lysates were cleared by centrifugation in an eppendorff tube (15 min at 14.000 r.p.m., 41C). Protein content was determined against a standardized control using the Pierce protein assay kit (Rockford, IL, USA). Equal amounts of protein were heated in SDS sample buffer (Laemmli) for 10 min at 701C, subjected to electrophoresis on 3-8% NuPAGE, and transferred onto nitrocellulose membranes. For immunoblot analysis of PR and p185 HERÀ2/neu , nonspecific binding on the nitrocellulose filter paper was minimized by blocking for 1 h at room temperature (RT) with TBS-T (25 mM Tris-HCl, 150 mM NaCl (pH 7.5), and 0.05% Tween 20) containing 5% (w/v) nonfat dry milk. The treated filters were washed in TBS-T and then incubated with primary antibodies (anti-PR mouse monoclonal antibody, Ab-8 from LabVision-NeoMarkers; Fremont, CA, USA, and anti-c-neu mouse monoclonal antibody, Ab-3 from Oncogene Research Products, San Diego, CA, USA) for 2 h at RT in TBS-T containing 1% (w/v) nonfat dry milk. The membranes were washed in TBS-T, horseradish peroxidase-conjugated secondary antibodies (Jackson Immuno Research, West Grove, PA, USA) in TBS-T were added for 1 h, and immunoreactive bands were visualized with ECL detection reagent (Pierce, Rockford, IL, USA). Blots were reprobed with an anti-b-actin goat polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) to control for protein loading and transfer. E 2 -free control samples. FAS inhibitor cerulenin exhibited antagonist effects by also decreasing the concentration of HER-2/neu oncoprotein in E 2 -stimulated Ishikawa cells (data not shown).
Estrogens induce conformational changes in the ER, which promote its nuclear accumulation, dimerization, and function as a ligand-activated transcription factor (Beato et al., 1996; Katzenellenbogen et al., 1996; Perlmann and Evans, 1997; Kawata, 2001) . To corroborate this E 2 -stimulated temporal-spatial distribution of ER in Ishikawa cells, we assessed cellular localization of ERa by indirect immunofluorescence before and after E 2 stimulation. As shown in Figure 2 (Top, panel i), ERa could be seen as fine granules of fluorescence more or less uniformly distributed mostly throughout the nuclei and also in the cytoplasmic compartment in E 2 -depleted Ishikawa cells. After the addition of E 2 , the faint nuclear staining of ERa in basal conditions did change to an intense nuclear labeling (Figure 2 , Top, panel ii), consistent with previous observations demonstrating that the addition of E 2 leads to almost complete nuclear translocation of ERa. Interestingly, ERa subcellular distribution was dramatically different in cerulenin-and C75-treated Ishikawa cells. In the presence of FAS inhibitors, a faint staining of ERa was detected almost entirely in the cytoplasm of E 2 -stimulated Ishikawa cells (Figure 2 , Top, panels iii and iv). These data demonstrate that pharmacological inhibition of FAS activity dramatically impairs E 2 -induced nuclear accumulation of ERa, strongly suggesting that pharmacological inhibition of FAS activity is directly interfering with steroid-receptor machinery in human endometrial adenocarcinoma cells. To further characterize the ability of FAS blockers to downregulate ERa in Ishikawa cells, the effects of FAS inhibition on the expression of ERa was evaluated by immunoblot. As single agents, cerulenin and C75 suppressed the basal levels of ERa (data not shown). As shown in Figure 2 Figure 2 Pharmacological inhibition of FAS activity impairs E 2 -induced nuclear accumulation of ERa and downregulates expression of ERa in Ishikawa cells. Top: Cells were seeded at a density of 1 Â 10 4 cells/well in a four-well chamber slide (Nalge Nunc International, Rochester, NY, USA). After 48 h incubation with: ethanol plus DMSO (control, panel i), 10
À9 M E 2 plus DMSO (panel ii), 10
À9 M E 2 plus 5 mg/ml cerulenin (panel iii) or 10 À9 M E 2 plus 5 mg/ml C75 (panel iv), cells were washed with PBS, fixed with 4% paraformaldehyde in PBS for 10 min, permeabilized with 0.2% Triton X-100/PBS for 15 min, and stored overnight at 41C with 10% horse serum in PBS. The cells were washed, and then incubated for 2 h with anti-ERa rabbit polyclonal antibody (sc-542 from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) diluted 1 : 200 in 0.05% Triton X-100/PBS. After extensive washes, the cells were incubated for 45 min with tetramethylrhodamine isothiocyanate (TRIC)-conjugated anti-rabbit IgG secondary antibody (Jackson Immunoresearch Labs, West Grove, PA, USA) diluted 1 : 200 in 0.05% Triton X-100/PBS. The cells were washed five times with PBS, mounted with VECTASHIELD þ DAPI, and indirect immunofluorescence was recorded as described in Figure 1d . Figure shows a representative immunostaining analysis. Similar results were obtained in three independent experiments. Bottom: Immunoblot analyses of ERa were carried out as described in Figure 1d using an anti-ERa rabbit polyclonal antibody mouse monoclonal (sc-542 from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Blots were reprobed with an anti-b-actin goat polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) to control for protein loading and transfer. Figure shows representative immunoblot analyses. Similar results were obtained in three independent experiments (bottom panels), E 2 treatment of Ishikawa cells caused a significant increase in the expression of ERa within 48 h. When combined with E 2 , cerulenin and C75 induced a dramatic downregulation of ERa protein at concentrations X5 mg/ml. Overall, these results suggest that cerulenin-and C75-induced downregulation of ERa expression may be one of the mechanisms through which FAS blockers act as E 2 antagonists in endometrial adenocarcinoma cells.
As cerulenin-and C75-induced inhibition of FAS activity effectively suppressed estrogenic effects at concentrations p10 mg/ml, we next evaluated whether the antiestrogenic effects of FAS inhibition demonstrated at the transcriptional level did correlate with changes in the stimulatory effects of E 2 in the growth of endometrial adenocarcinoma cells. Ishikawa cells were starved from E 2 in phenol red-free medium containing charcoal-treated calf serum, seeded in tissue culture plates and then grown in the absence or presence of 10 À9 M E 2 for 6 days. We observed that cerulenin and C75 did not enhance the growth of endometrial carcinoma cells in the absence of E 2 . In fact, cerulenin and C75 treatments reduced E 2 -independent Ishikawa cell growth in a dose-dependent manner ( Figure 3a) . As expected, the growth of Ishikawa cells was significantly enhanced by E 2 (B135%), and this E 2 -growth stimulatory effect was sensitive to the pure antiestrogen ICI 182,780. Interestingly, low concentrations of cerulenin and C75 (o5 mg/ml) reversed E 2 -enhanced Ishikawa cell proliferation (Figure 3b ). Under the same conditions, high concentrations of cerulenin and C75 (45 mg/ml) completely inhibited endometrial adenocarcinoma cell growth. Early studies previously demonstrated that in hormone-responsive human breast cancer cells (MCF-7 and T47-D), E 2 stimulates cell growth and concomitant FAS expression (Joyeux et al., 1989; Chalbos et al., 1992; Kalkhoven et al., 1994) . Corroborating these observations in endometrial adenocarcinoma cells, we found that E 2 stimulation significantly upregulated FAS expression in Ishikawa cells, while the pure antiestrogen ICI 182,780 significantly abolished this effect, as revealed by Western blotting analyses (Figure 3b ). To evaluate whether the accumulation of FAS was due to an increase in number of cells that expressed FAS as well as in the level of FAS expression in individual cells, we monitored FAS localization using immunofluorescent microscopy before and after the addition of E 2 . FAS was localized primarily in the cytosol when its cellular distribution was explored by direct visualization using fluorescence microscopy of Ishikawa cells in the absence of E 2 (Figure 3c , panel i). As with Western blotting, we found that E 2 treatment dramatically increased the cytoplasmic accumulation of FAS in endometrial adenocarcinoma Ishikawa cells (Figure 3c, panel ii) . The difference in FAS intensity was evident and highly reproducible. Interestingly, exposure to suboptimal (noncytotoxic) concentrations of C75 induced a significant decrease in the cytoplasmic accumulation of FAS in E 2 -stimulated Ishikawa cells breast cancer cells (Figure 3c, panel iii) . A similar reversion of E 2 -induced upregulation of FAS expression was observed in the presence of cerulenin (data not shown).
In the absence of E 2 , the growth of Ishikawa cells was significantly enhanced in the presence of TAM (B125%), and the pure antiestrogen ICI 182,780 had no effect on the TAM-enhanced proliferation in Ishikawa cells (Figure 3d ). This finding is consistent with the results from the transcriptional data described above, and suggests that E 2 and TAM use different mechanisms to transactivate ER-dependent signaling and stimulate the growth of endometrial cancer cells. Interestingly, when added in the presence of TAM, FAS blockers cerulenin and C75 completely inhibited TAMenhanced cell proliferation in a dose-dependent manner (Figure 3d ). Taken together, these results indicate that upregulation of FAS accompanies E 2 -induced cell proliferation in human endometrial adenocarcinoma cells. Interestingly, inhibition of FAS activity also indirectly modulates FAS expression, likely through its antiestrogenic effects, thus evidencing a complex bidirectional crosstalk between ER and FAS signalings in Ishikawa cells. Since cerulenin-and C75-induced inhibition of FAS activity promoted cytostatic and cytotoxic effects in the absence or presence of E 2 and TAM, it is reasonable to suggest that FAS activity is necessary for hormone-dependent and -independent endometrial adenocarcinoma cell proliferation.
In order to examine the possibility that cerulenin-and C75-induced inhibition of FAS activity related to a decrease in cell viability, we evaluated the metabolic status of cerulenin-and C75-treated Ishikawa cells as judged by the mitochondrial conversion of the tetrazolium salt, MTT (3-4, 5-dimethylthiazol-2-yl-2, 5-diphenyl-tetrazolium bromide), to its formazan product (MTT assay) in the absence or presence of E 2 . Cerulenin and C75 treatments significantly reduced cell viability in a dose-dependent fashion in Ishikawa cells (Figure 3e ). When the efficacy of cerulenin and C75 was evaluated by calculating the IC 50 value (the dose of drug required producing a 50% reduction in cell viability), we observed a similar cerulenin activity in the presence or presence of E 2 . Induction of apoptosis has been suggested to represent one mechanism of cytotoxicity that follows cerulenin-induced inhibition of FAS activity in human breast cancer cell models (Pizer et al., 1996a (Pizer et al., , 2000 Li et al., 2001) . In our studies, ceruleninand C75-associated apoptosis was assessed by using the Cell Death Detection ELISA, which is based on quantitative enzyme-immunoassay-principle using mouse monoclonal antibodies directed against DNA and histones and allows the specific determination of mono-and oligonucleosomes that are released into the cytoplasm of cells dying from apoptosis. The x-fold increase in apoptosis was calculated by comparing the optical density readings from C75-and cerulenin-treated samples, with the values of the untreated control (Figure 3f ). Exposure of Ishikawa cells to increasing concentrations of C75 and cerulenin resulted in a dramatic dose-dependent increase in apoptotic cell death over untreated cells (up to Bsix-and fivefold at 10 mg/ml, respectively; white columns in Figure 3f ).
Interestingly, Ishikawa cells were slightly less sensitive to the apoptotic effects of FAS inhibitors when cotreated with E 2 (black columns in Figure 3f ).
To further investigate how pharmacological inhibition of FAS activity interrupted E 2 -dependent mitogenic signaling, we evaluated the effects of cerulenin and C75 in the levels of cyclin-dependent kinases inhibitors (CDK i s) p21 WAF1/CIP1 and p27
Kip1
, both playing essential roles in hormonedependent tumor cell growth. After 48 h exposure to increasing concentrations of FAS inhibitors, a dosedependent increase of p21 WAF1/CIP1 and p27 Kip1 expression was observed in Ishikawa cells (Figure 3g, top left) . p21 WAF1/CIP1 accumulation did peak at 8 mg/ml cerulenin and then decreased at 10 mg/ml cerulenin, while a maximal induction of p27
Kip1 was observed at 10 mg/ml cerulenin. Cerulenin treatment upregulated p53 expression and the magnitude of this induction paralleled that observed for p21 WAF1/CIP1 , suggesting that cerulenin-promoted activation of p21 WAF1/CIP1 is a p53-regulated response in Ishikawa cells. A dramatic accumulation of p21 WAF1/CIP1 and p27 Kip1 was also observed after C75 exposure in Ishikawa cells (Figure 3g , top right). We finally evaluated how cerulenin treatment affected the cellular localization of p21 WAF1/CIP1 and p27
. We observed by immunofluorescence microscopy that a faint staining of p21 WAF1/CIP1 and p27 Kip1 could be detected in both nucleus and cytosol in proliferating Ishikawa cells (Figure 3g , panels i and ii). Treatment with growth-inhibitory doses of cerulenin (5 mg/ml) resulted in a dramatic accumulation of p21 WAF1/CIP1 and p27 Kip1 in Ishikawa cell nuclei (Figure 3g , panels ii-iv). Treatment with C75 also resulted in an almost complete translocation of p21 WAF1/CIP1 and p27 Kip1 from cytosol to cell nuclei (data not shown). These data imply that modulation of both the expression and the cellular localization of p21 WAF1/CIP1 and p27 Kip1 is a novel molecular response that follows pharmacological inhibition of FAS activity and precedes apoptotic cell death in endometrial adenocarcinoma Ishikawa cells.
To rule out a role for non-FAS cerulenin-and C75-mediated effects on ER-dependent signaling, we used an entirely different approach to interfere with FAS activity in endometrial adenocarcinoma Ishikawa cells. This approach was based on selective FAS gene silencing, using the potent and highly sequence-specific mechanism of RNA interference (RNAi). RNAi is a cellular process resulting in enzymatic cleavage and breakdown of mRNA, guided by sequence-specific double-stranded RNA oligonucleotides (siRNA; Zamore et al., 2000; Elbashir et al., 2001; Harborth et al., 2001; De Schrijver et al., 2003) . If cerulenin-and C75-dependent blockade of FAS activity was the most important molecular mechanism responsible for cerulenin-and C75-induced inhibition of ER-dependent signaling, we hypothesized that downregulation of FAS expression should lead to decreased E 2 -and TAM-stimulated ER transcriptional activity in FAS RNAi-transfected Ishikawa cells. To specifically silence the FAS gene, Ishikawa cells were transfected with siRNA-targeting FAS mRNA. As a control for specificity of RNAi, cells were transfected with a nonspecific control pool of RNAi. Silencing of FAS expression was already visible 48 h after transfection, reached optimal inhibition after 72 h, and lasted for at least another 72 h (through 144 h after transfection; data not shown). Figure 4 (top panels, left) (Figure 4, bottom panels, right) . Similarly, RNAi-mediated downregulation of FAS expression significantly increased TAM EC 50 from B2 Â 10 À11 M TAM in Ishikawa control cells to B8 Â 10 À9 M E 2 in Figure 3 (a-d) Pharmacological inhibition of FAS activity exhibits cytostatic and cytotoxic effects and attenuates E 2 -induced accumulation of FAS in Ishikawa cells. Cells were grown in phenol red-free IMEM and 5% CCS for 5 days in T75 flasks. Cells were trypsinized and replated in 24-well plates at a density of 10 000 cells/well. Cells were incubated for 18 h to allow for attachment, after which a zero time point was determined. Cells were treated with phenol red-free IMEM and 5% CCS containing either E 2 (10 À9 M), ICI 182,780 (10 À7 M), TAM (10 À8 M), cerulenin (1-10 mg/ml), C75 (1-10 mg/ml), combinations of these compounds as specified, and ethanol (v/ v) or DMSO (v/v) vehicles alone. Cells were counted at days 0, 3, and 6 with a Coulter Counter (Coulter Electronics, Inc., Hialeah, FL, USA). All assays were performed at least three times in triplicate. The data are presented as mean of number cells Â 10 4 /well (columns)7s.d. (bars) after 6 days treatment. In (b), Ishikawa cells were treated for 48 h with 10 À9 M E 2 in the absence or presence of 10 À7 M ICI 182,780. Immunoblot analysis of FAS was carried out as described in Figure 1d using a mouse monoclonal antibody against FAS (clone M3, generously provided by Dr E Pizer, Johns Hopkins University, Baltimore, MD, USA). In (c), Ishikawa cells were treated for 48 h with ethanol plus DMSO (control, panel i), 10
À9 M E 2 plus DMSO (panel ii), or 10 À9 M E 2 plus 5 mg/ml C75 (panel iii). Cells were fixed and then incubated for 2 h with a mouse IgG 1 FAS monoclonal antibody (clone 23, BD Biosciences Pharmingen, CA, USA) diluted 1 : 200 in 0.05% Triton X-100/PBS. After labeling, cells were extensively washed, and localization of FAS enzyme was detected by indirect immunofluorescence by incubating with FITC-conjugated anti-mouse IgG as described in Figure 1d , and p27
Kip1 expression, and promotes nuclear accumulation of p21 WAF1/CIP1 and p27 Kip1 in Ishikawa cells. (e) Cerulenin (top)-and C75 (bottom)-induced effects on cell viability were determined using a standard colorimetric MTT reduction assay. Cells in exponential growth were harvested by trypsinization and seeded at a concentration of 3 Â 10 3 cells/200 ml/well onto 96-well plates, and allowed an overnight period for attachment. Such conditions did allow the control untreated cells to become confluent after B5 days. Then the medium was removed and fresh medium along with various concentrations of cerulenin (1-10 mg/ml) in the presence or absence of 10 À9 M E 2 were added to the cultures. Compounds were not renewed during the entire period of cell exposure, and control cells without agents were cultured using the same conditions. Following treatment, the medium was removed and replaced by fresh drug-free medium (100 ml/well), and MTT was added to each well. After incubation for 3-4 h at 371C, the supernatants were carefully aspirated, 100 ml of DMSO were added to each well, and the plates agitated to dissolve the MTT-formazan crystals. Absorbances were measured at 570 nm using a multiwell plate reader. The cell viability effects from exposure of Ishikawa cells to cerulenin alone (dashed line) and their combination with E 2 were analysed generating concentration-effect curves as a plot of the fraction of unaffected (surviving) cells vs drug concentration. Dose-response curves were plotted as percentages of the control cell absorbances, which were obtained from control wells treated with appropriate concentrations of the compounds vehicles that were processed simultaneously. For each treatment, cell viability was evaluated as a percentage using the following equation: (A 570 of treated sample/ A 570 of untreated sample) Â 100. All assays were performed at least three times in triplicate. The data are presented as mean of cell viability7s.d. (bars). (f) Quantification of apoptotic cell death was determined by Cell Death ELISA (Roche Biochemicals), which measures cytoplasmic histone-DNA fragments produced during apoptosis. Briefly, Ishikawa cells (5 Â 10 3 /well) were grown in 96-well plates and treated, in duplicates, for 72 h with the indicated doses of C75 and cerulenin in the presence (black columns) or absence (white columns) of 10 À9 M E 2 . After treatment, the 96-well plates were centrifuged (200 g) for 10 min. The supernatant was discharged, lysis buffer was added, and samples were incubated at room temperature (RT) for 30 min following the manufacturer's instructions. Anti-histone biotin and anti-DNA peroxidase antibodies were added to each well and incubated at RT for 2 h. After three washes, the peroxidase substrate was added to each well, and the plates were read at 405 nm at multiple time intervals. The enrichment of histone-DNA fragments in treated cells was expressed as fold increase in absorbance as compared with control (vehicle-treated) cells, which were taken as 1.0-fold. All assays were performed at least three times in duplicate. The data are presented as mean (columns) , and p27
Kip1 were carried out as described in Figure 1d using anti-p53 mouse monoclonal (Ab-5, Oncogene Research Products; San Diego, CA, USA), anti-p21 WAF1/CIP1 mouse monoclonal (PharMingen; San Diego, CA, USA), and anti-p27
Kip1 rabbit polyclonal (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) antibodies. Bottom panels. Cells were seeded at a density of 1 Â 10 4 cells/well in a four-well chamber slide, and after 48 h incubation with 10 À9 M E 2 in the absence (control panels, i and ii) or presence (iii and iv) of 5 mg/ml cerulenin, p21 WAF1/CIP1 and p27 Kip1 cellular localization was evaluated after 2 h incubation with anti-p21 WAF1/CIP1 mouse monoclonal and p27 Kip1 rabbit polyclonal antibodies diluted 1 : 200 in 0.05% Triton X-100/PBS. After labeling, cells were extensively washed, and localization of p21 WAF1/CIP1 and p27 Kip1 was detected by indirect immunofluorescence as described in Figure 1d The data presented here demonstrate that the fatty acid-like antibiotic cerulenin, a valuable experimental tool in studies of lipogenesis through its ability to specifically block FAS activity (Christie et al., 1981) , functions as a novel selective modulator of ER signaling in endometrial cancer. C75, a novel slow-binding inhibitor of FAS activity (Kuhajda et al., 2000b) , has been shown to cause significant weight loss through decreased hypothalamic neuropeptide Y production, to increase peripheral energy utilization and energy consumption through activation of carnitine O-palmitoyltransferase-1 (CPT-1) enzyme, and to increase glucose -001206-13) . At 72 h after transfection, one set of RNAi FAS-transfected Ishikawa cells were used for FAS activity assays (not shown) and immunoblotting analyses of FAS expression (top panels, left). A second set of RNAi FAS-transfected Ishikawa cells were exposed to medium containing E 2 (bottom panels, left) or TAM (bottom panels, right) concentrations ranging from 10 À12 to 10 À8 M for 24 h, harvested and assayed for luciferase activity as described above. Maximal stimulation of E 2 -and TAM-stimulated ERE-Luciferase activity (E max ) and the agonist concentration achieving half this effect (EC 50 ) were obtained from curve-fits of individual concentration-response curves (by order 3 of polynomial, with all R values 40.95). The data shown here are from three separate experiments, represented as the mean (columns)7s.d. (bars). A third set of E 2 -stimulated FAS RNAi-transfected Ishikawa cells was used for immunoblotting analyses of ERa, PR, p21 WAF1/CIP1 , p27 Kip1 , metabolism in central nervous system (Loftus et al., 2000; Kim et al., 2002; Kumar et al., 2002; Shimokawa et al., 2002; Thupari et al., 2002; Wortman et al., 2003 (Webb et al., 1998; Barsalou et al., 1998) . In these earlier studies, however, Ishikawa cells were used as a cell system to evaluate the TAM effects in endometrial cancer cells without experimental evidence of ER expression levels, which are found to be expressed at various levels among Ishikawa cell sublines (Holinka et al., 1986; Nishida et al., 1996; Nishida, 2002) . In this study, we examined the effects of TAM on endometrial cancer using Ishikawa cells expressing a functional ER signaling, as determined by immunobloting and indirect immunofluorescence of ERa, by measuring activity levels of AP, an estrogen-inducible marker enzyme in Ishikawa cells, and by evaluating E 2 -inducible genes PR and HER-2/neu. Moreover, the TAM-stimulated endogenous ER transcriptional activity and cell growth showed in our study support the results from Sakamoto et al. (2002) , demonstrating that ER-mediated effects of TAM on Ishikawa endometrial cancer cells may be involved in the stimulatory effect of TAM on the development and/or progression of endometrial cancer. From a clinical perspective, our observations evidencing that both the pharmacological blockade and the RNAiinduced silencing of tumor-associated FAS signaling antagonizes the agonist activity of TAM on endogenous ERE-dependent transcriptional activity strongly suggest that FAS-dependent lipogenesis, once considered largely an anabolic-energy-storage pathway, may provide means for therapeutic prevention and/or intervention in the endometrial cancer scenery.
Additionally, our data reveal that pharmacological inhibition of FAS activity exerts an antiproliferative effect in Ishikawa cells in the presence of E 2 . Interestingly, E 2 -induced Ishikawa cell proliferation is accompanied by upregulation of FAS expression, while inhibition of FAS activity significantly reverses E 2 -stimulated FAS accumulation, likely through the ability of FAS blockers to modulate ER signaling. These results suggest that a complex bidirectional crosstalk between ER and FAS signaling is taking place in Ishikawa cells. In the absence of E 2 , FAS blockers inhibit Ishikawa cell proliferation in a dose-dependent manner, while the combination of TAM and FAS inhibitors also determines a suppression of TAMstimulated Ishikawa cell growth. Taken together, these data imply that the antiproliferative effect that follows blockade of FAS activity in Ishikawa cells may be mediated by both hormone-dependent and -independent mechanisms. Moreover, it can be assumed that the decrease in the growth of Ishikawa cells resulting from FAS activity inhibition was due to a decrease in cell viability. Our results further prove that antimetabolite drug-induced inhibition of FAS activity triggers apoptosis in endometrial adenocarcinoma Ishikawa cells. Although the molecular mechanisms operating in cerulenin-and C75-induced apoptosis were not fully addressed, it is reasonable to suggest that cerulenin-and C75-induced inhibition of FAS activity may act as an SERM inhibiting endometrial adenocarcinoma cell growth and inducing apoptosis through the modulation of cell cycle regulators and apoptosisregulating proteins such as the CDK i s p27
Kip1 and p21 WAF1/CIP1 . p27
Kip1 and p21 WAF1/CIP1 are essential mediators of cell growth arrest by antiestrogens through their ability to bind the cyclin E-Cdk2 complex and function as suppressors of E 2 -promoted cell cycle (Foster and Wimalasena, 1996; Planas-Silva and Weinberg, 1997; Prall et al., 1997; Cariou et al., 2000) . Here, we found that treatment with FAS inhibitors resulted in higher cellular levels of p27
Kip1 and dramatically increased the ratio of nuclear p27
Kip1 to cytoplasmic p27
. In addition, pharmacological blockade of FAS activity did upregulate p21 WAF1/CIP1 in a p53-dependent manner, and markedly augmented the ratio of nuclear p21 WAF1/CIP1 to cytoplasmic p21 WAF1/CIP1 . Although the ultimate determinants of a molecular interaction between tumorassociated FAS hyperactivity and CDK i s p27
Kip1 and p21 WAF1/CIP1 in endometrial adenocarcinoma cells require further investigation, it is likely that interruption of ER signaling following FAS inhibition is increasing the amount of nuclear p27
Kip1 and p21 WAF1/CIP1 available for binding to and inhibiting Cdk2 activity. This, in turn, may lead to a prolonged cell cycle arrest and apoptotic cell death of Ishikawa cells. Moreover, it has been demonstrated that normal endometrial cells show strong nuclear expression of p27 Kip1 , whereas strongly reduced or abolished expression of p27 Kip1 was found in endometrial carcinomas (Bamberger et al., 1999) . It thus seems that p27
Kip1 expression is essential for the control of normal endometrial proliferation, and reduced or absent p27
Kip1 expression may be an important step in endometrial carcinogenesis (Bamberger et al., 1999) . In this regard, upregulation of p27
Kip1 has been involved in the progestins-induced growth suppression of Ishikawa cells (Shiozawa et al., 1998) . Our current study demonstrating that nuclear accumulation of p27
Kip1 is a prominent molecular response following cerulenin and C75 treatments support the notion that FAS is playing an active role in the progression of human endometrial carcinomas (Pizer et al., 1998b) . In agreement with this view, RNAi-mediated silencing of FAS gene reproduced the antiproliferative and apoptotic effects of chemical FAS inhibitors, also causing a prominent accumulation of p21 WAF1/CIP1 and p27 Kip1 in Ishikawa cells.
By definition, SERMs exert estrogen agonist action in some target tissues while acting as estrogen antagonists in others. Preliminary results in our laboratory indicate that chemical FAS inhibitors, as well as FAS RNAi, act as superagonists of E 2 -dependent ER-driven transcriptional activation in human breast cancer cells through a mechanism involving the hyperactivation of MAPK/ERa crosstalk (unpublished observations). Although early, these data might indicate that inhibitors of FAS activity might be novel members of the SERM family. Nevertheless, our current data not only reveal a new molecular mechanism through which chemical FAS inhibitors exert their antitumor activity in endometrial cancer cells, but also suggest the existence of a complex molecular connection between FAS-and ER-dependent signalings in human endometrial adenocarcinoma. If chemically stable FAS inhibitors demonstrate systemic anticancer effects of FAS inhibition in vivo, additional preclinical studies to characterize the action of cerulenin-and C75-related compounds should be of great interest as the specific blockade of FAS activity may provide a protective molecular tool against endometrial carcinoma associated with TAM-based breast cancer therapy. Moreover, this study provides the rationale for the development of novel tumor cell-selective vector systems able to deliver RNAi targeting tumor-associated FAS for the prevention and treatment of human endometrial cancer.
